GSK - International Biopharmaceutical Industry

news

GSK wagers $2.1B on Affinivax and its next-generation pneumonia vaccine

GSK has agreed to acquire Affinivax in a deal announced Tuesday, betting more than $3 billion that the eight-year-old startup’s technology can lead to a more effectiv...

6 June 2022 news Affinivax | GSK

Continue Reading →

news

Pfizer to exit GSK consumer health joint venture after spinoff

Dive Brief: Pfizer plans to sell its shares in a consumer health joint venture with GlaxoSmithKline after the business is spun off into a new standalone corporatio...

6 June 2022 news consumer | GSK

Continue Reading →

news

GSK acquires Sierra Oncology, betting $2B on a bone cancer drug with a long history

GlaxoSmithKline has agreed to acquire Sierra Oncology for $1.9 billion in a bet that an experimental drug the small biotech developed is on the cusp of becoming a val...

14 April 2022 news cancer | Drug

Continue Reading →

news

GSK partners with LifeMine as startups advance plans to make drugs from fungi

Finding drugs from fungi has been a mix of serendipity and scientific discovery that, over the years, led to medicines like penicillin, the first statin and the immun...

25 March 2022 news fungi | GSK

Continue Reading →

news

Sanofi and GSK, after delays, to seek clearance for COVID-19 vaccine

Sanofi and GlaxoSmithKline plan to seek authorization for their experimental coronavirus vaccine in the U.S. and abroad after their shot prevented COVID-19 in a large...

24 February 2022 news coronavirus | COVID-19

Continue Reading →

news

GSK loses R&D chief Barron to high-powered startup amid investor pressure

Hal Barron, GlaxoSmithKline's top scientist and architect of the company's plans to revitalize its drug research, will step down from his role later this year to lead...

20 January 2022 news Barron | Biotech

Continue Reading →

news

Sanofi, GSK say COVID vaccine works as booster, but delay key study results

Sanofi and GSK expected to have definitive results for their long-delayed coronavirus vaccine by now, having redesigned their shot after an initial formulation disapp...

16 December 2021 news booster | coronavirus vaccine

Continue Reading →

news

GSK sets sights on brain diseases through Oxford partnership

Diseases of the brain and central nervous system have been notoriously challenging to treat, even for the world's largest and most well-resourced drug companies. But...

13 December 2021 news Alzheimer | brain diseases

Continue Reading →

news

Vaccine from Medicago, GSK protective against COVID-19 in large study

Most of the vaccines approved to date use either messenger RNA or DNA to coax the body's cells to produce the spike protein, or are synthetic versions of the spike th...

10 December 2021 news COVID-19 | DNA

Continue Reading →

news

Early tests suggest Vir, GSK antibody could hold up versus omicron

Omicron's detection last week triggered travel restrictions and renewed public health measures around the world as scientists and government officials warned the vari...

3 December 2021 news Antibody | GSK

Continue Reading →

Current Edition

Upcoming Events

Advertisement

GSK wagers $2.1B on Affinivax and its next-generation pneumonia vaccine

Pfizer to exit GSK consumer health joint venture after spinoff

GSK acquires Sierra Oncology, betting $2B on a bone cancer drug with a long history

GSK partners with LifeMine as startups advance plans to make drugs from fungi

Sanofi and GSK, after delays, to seek clearance for COVID-19 vaccine

GSK loses R&D chief Barron to high-powered startup amid investor pressure

Sanofi, GSK say COVID vaccine works as booster, but delay key study results

GSK sets sights on brain diseases through Oxford partnership

Vaccine from Medicago, GSK protective against COVID-19 in large study

Early tests suggest Vir, GSK antibody could hold up versus omicron

International Biopharmaceutical Industry